
WCLC 2018 — Advanced NSCLC: immuno-oncology less commonly used than expected
(...)
The resource you are trying to access is only available for registered users. To continue please login or create a FREE Univadis® account.
-
登入
-
Register to Univadis at NO COST
- Find relevant information quickly
- Regular updates of specialty information
- Helpful resources at the point of care
- Educate your patients with quality health information
- Access to world-leading medical publishers
Featured channels
Most recent
-
ASCO-GU 2019—Avelumab+axitinib bests sunitinib in previously untreated clear-cell aRCC
Tuesday 19 February 2019
-
ASCO-GU 2019—Darolutamide improves MFS in castration-resistant prostate cancer
Tuesday 19 February 2019
-
ASCO-GU 2019—Enzalutamide+ADT extends radiographic PFS in mHSPC
Tuesday 19 February 2019
-
ASCO-GU 2019—OS advantage for abiraterone+prednisone+ADT in metastatic prostate cancer
Tuesday 19 February 2019
-
ASCO-GU 2019—Pembrolizumab+axitinib better than sunitinib in advanced or metastatic clear-cell RCC
Tuesday 19 February 2019
-
ASCO-GI 2019—Durvalumab-tremelimumab extends OS in refractory CRC
Wednesday 23 January 2019
-
ASCO-GI 2019—FTD/TPI effective for mGC regardless of prior gastrectomy
Wednesday 23 January 2019
-
ASCO-GI 2019—NACT tops upfront surgery for PDAC in phase 2/3 trial
Wednesday 23 January 2019
-
ASCO-GI 2019—Pembrolizumab shows OS advantage in PD-L1 esophageal cancer
Wednesday 23 January 2019
Most viewed
Most popular
Keep up with oncology literature in minutes, every day
Get your daily dose of the latest evidence published in your cancer area of practice
Get my daily Newsletter